Enrolment commences for Phase I human clinical trial
Avecho Biotechnology Limited (ASX:AVE) has announced the enrolment of our first healthy volunteers for our Phase I pharmacokinetic (PK) human clinical trial to characterise the absorption profile of cannabidiol (CBD) from our CBD soft-gel product.
The Study will measure the safety and absorption profile of the CBD soft-gel product, and will compare the absorption of CBD at two different doses; 75 mg and 150 mg, in alignment with the TGA’s specified maximum daily dose of 150 mg for over the counter products. Dosing will begin in October.
Avecho CEO, Dr Paul Gavin, said:
“We have invested time this year on optimising and completing the product with Catalent, a respected global leader in the development of drug technologies, to ensure the dosage form was the highest possible standard. We are excited to see how it performs.”